A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Latest Information Update: 13 May 2022
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Apr 2021 Primary endpoint (Phase II - Disease Control Rate at 4 Months) has not been met, as per results published in the British Journal of Cancer.
- 07 Apr 2021 Results published in the British Journal of Cancer